Literature DB >> 31619689

Imbalance in the response of pre- and post-synaptic components to amyloidopathy.

Terri-Leigh Stephen1,2, Francesco Tamagnini1,3,4, Judith Piegsa1,4, Katherine Sung1, Joshua Harvey1, Alice Oliver-Evans1, Tracey K Murray1, Zeshan Ahmed1, Michael L Hutton1, Andrew Randall4, Michael J O'Neill1,5, Johanna S Jackson6,7.   

Abstract

Alzheimer's disease (AD)-associated synaptic dysfunction drives the progression of pathology from its earliest stages. Amyloid β (Aβ) species, both soluble and in plaque deposits, have been causally related to the progressive, structural and functional impairments observed in AD. It is, however, still unclear how Aβ plaques develop over time and how they progressively affect local synapse density and turnover. Here we observed, in a mouse model of AD, that Aβ plaques grow faster in the earlier stages of the disease and if their initial area is >500 µm2; this may be due to deposition occurring in the outer regions of the plaque, the plaque cloud. In addition, synaptic turnover is higher in the presence of amyloid pathology and this is paralleled by a reduction in pre- but not post-synaptic densities. Plaque proximity does not appear to have an impact on synaptic dynamics. These observations indicate an imbalance in the response of the pre- and post-synaptic terminals and that therapeutics, alongside targeting the underlying pathology, need to address changes in synapse dynamics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31619689      PMCID: PMC6795896          DOI: 10.1038/s41598-019-50781-1

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  54 in total

1.  Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques.

Authors:  Robert M Koffie; Melanie Meyer-Luehmann; Tadafumi Hashimoto; Kenneth W Adams; Matthew L Mielke; Monica Garcia-Alloza; Kristina D Micheva; Stephen J Smith; M Leo Kim; Virginia M Lee; Bradley T Hyman; Tara L Spires-Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-19       Impact factor: 11.205

2.  Altered intrinsic neuronal excitability and reduced Na+ currents in a mouse model of Alzheimer's disease.

Authors:  Jon T Brown; Jeannie Chin; Steven C Leiser; Menelas N Pangalos; Andrew D Randall
Journal:  Neurobiol Aging       Date:  2011-07-27       Impact factor: 4.673

3.  Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative.

Authors:  William E Klunk; Brian J Bacskai; Chester A Mathis; Stephen T Kajdasz; Megan E McLellan; Matthew P Frosch; Manik L Debnath; Daniel P Holt; Yanming Wang; Bradley T Hyman
Journal:  J Neuropathol Exp Neurol       Date:  2002-09       Impact factor: 3.685

4.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2010-01       Impact factor: 44.182

5.  Remodeling of synaptic structure in sensory cortical areas in vivo.

Authors:  Ania K Majewska; Jessica R Newton; Mriganka Sur
Journal:  J Neurosci       Date:  2006-03-15       Impact factor: 6.167

6.  Complement and microglia mediate early synapse loss in Alzheimer mouse models.

Authors:  Victoria F Beja-Glasser; Bianca M Nfonoyim; Soyon Hong; Arnaud Frouin; Shaomin Li; Saranya Ramakrishnan; Katherine M Merry; Qiaoqiao Shi; Arnon Rosenthal; Ben A Barres; Cynthia A Lemere; Dennis J Selkoe; Beth Stevens
Journal:  Science       Date:  2016-03-31       Impact factor: 47.728

7.  Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease.

Authors:  Melanie Meyer-Luehmann; Tara L Spires-Jones; Claudia Prada; Monica Garcia-Alloza; Alix de Calignon; Anete Rozkalne; Jessica Koenigsknecht-Talboo; David M Holtzman; Brian J Bacskai; Bradley T Hyman
Journal:  Nature       Date:  2008-02-07       Impact factor: 49.962

8.  Network Disruption and Cerebrospinal Fluid Amyloid-Beta and Phospho-Tau Levels in Mild Cognitive Impairment.

Authors:  Leonides Canuet; Sandra Pusil; María Eugenia López; Ricardo Bajo; José Ángel Pineda-Pardo; Pablo Cuesta; Gerardo Gálvez; José María Gaztelu; Daniel Lourido; Guillermo García-Ribas; Fernando Maestú
Journal:  J Neurosci       Date:  2015-07-15       Impact factor: 6.167

9.  Increased axonal bouton dynamics in the aging mouse cortex.

Authors:  Federico W Grillo; Sen Song; Leonor M Teles-Grilo Ruivo; Lieven Huang; Ge Gao; Graham W Knott; Bohumil Maco; Valentina Ferretti; Dawn Thompson; Graham E Little; Vincenzo De Paola
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-29       Impact factor: 11.205

10.  Neuronal Aβ42 is enriched in small vesicles at the presynaptic side of synapses.

Authors:  Yang Yu; Daniel C Jans; Bengt Winblad; Lars O Tjernberg; Sophia Schedin-Weiss
Journal:  Life Sci Alliance       Date:  2018-06-14
View more
  4 in total

1.  Resting state EEG biomarkers of cognitive decline associated with Alzheimer's disease and mild cognitive impairment.

Authors:  Amir H Meghdadi; Marija Stevanović Karić; Marissa McConnell; Greg Rupp; Christian Richard; Joanne Hamilton; David Salat; Chris Berka
Journal:  PLoS One       Date:  2021-02-05       Impact factor: 3.240

2.  Cysteine string protein alpha accumulates with early pre-synaptic dysfunction in Alzheimer's disease.

Authors:  Huzefa Rupawala; Keshvi Shah; Caitlin Davies; Jamie Rose; Marti Colom-Cadena; Xianhui Peng; Lucy Granat; Manal Aljuhani; Keiko Mizuno; Claire Troakes; Beatriz Gomez Perez-Nievas; Alan Morgan; Po-Wah So; Tibor Hortobagyi; Tara L Spires-Jones; Wendy Noble; Karl Peter Giese
Journal:  Brain Commun       Date:  2022-07-23

3.  Stable cerebrospinal fluid neurogranin and β-site amyloid precursor protein cleaving enzyme 1 levels differentiate predementia Alzheimer's disease patients.

Authors:  Bjørn Eivind Kirsebom; Grit Richter; Kaja Nordengen; Dag Aarsland; Geir Bråthen; Betty M Tijms; Pieter Jelle Visser; Johanna Nilsson; Per Selnes; Milica G Kramberger; Bengt Winblad; Knut Waterloo; Berglind Gísladóttir; Kaj Blennow; Tormod Fladby
Journal:  Brain Commun       Date:  2022-09-24

4.  Antibody screening using a human iPSC-based blood-brain barrier model identifies antibodies that accumulate in the CNS.

Authors:  Julia V Georgieva; Loukas I Goulatis; Charles C Stutz; Scott G Canfield; Hannah W Song; Benjamin D Gastfriend; Eric V Shusta
Journal:  FASEB J       Date:  2020-07-30       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.